reference/9095631

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9095631

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	217
issn	0168-8278
issueIdentifier	2
pageRange	212-217
publicationName	Journal of Hepatology
startingPage	212
bibliographicCitation	Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996 Aug;25(2):212–7. doi: 10.1016/s0168-8278(96)80076-6. PMID: 8878784.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7301ca97701b621521cb08c21a641819 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_327ff6fca64c4e9fc8c32ae7639b3033 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee77eef21440bf85cb5426ae9bbd9e6e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cea9d5e5e41a7156a431274a06ab323f http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9697-2557 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5a39a02faa8d0f27912f09688620cdad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7a7b7b374ac8df9438124e5f53a8a07 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_49fd8f40c5f0d2eeffd48f134d51e67b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dfa8960f8aa2209be2d25835b4458380 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4978-0875 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a2e5ca5a064c02ffb9a3ed87ff3ed8ac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d764033a2b1caf656503e63c307a4e85 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_278efa90e489a51373bb276f0a365e4b
date	199608
identifier	https://pubmed.ncbi.nlm.nih.gov/8878784 https://doi.org/10.1016/s0168-8278%2896%2980076-6
isPartOf	https://portal.issn.org/resource/ISSN/0168-8278 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4786
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients
discusses	http://id.nlm.nih.gov/mesh/M0025711 http://id.nlm.nih.gov/mesh/M0001435 http://id.nlm.nih.gov/mesh/M0218277 http://id.nlm.nih.gov/mesh/M0012581 http://id.nlm.nih.gov/mesh/M0009493 http://id.nlm.nih.gov/mesh/M0014578 http://id.nlm.nih.gov/mesh/M0022149 http://id.nlm.nih.gov/mesh/M0003559
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009363Q000097 http://id.nlm.nih.gov/mesh/D008074Q000097 http://id.nlm.nih.gov/mesh/D006526Q000628 http://id.nlm.nih.gov/mesh/D016898Q000627 http://id.nlm.nih.gov/mesh/D002352Q000097 http://id.nlm.nih.gov/mesh/D006023Q000097
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006526Q000503 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D014408 http://id.nlm.nih.gov/mesh/D006526Q000097 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D005544 http://id.nlm.nih.gov/mesh/D006509Q000503 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D017211 http://id.nlm.nih.gov/mesh/D002353Q000097 http://id.nlm.nih.gov/mesh/D000951 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D006509Q000628 http://id.nlm.nih.gov/mesh/D002908 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D006509Q000097 http://id.nlm.nih.gov/mesh/D015331
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3a398a9729e4a4ba881023dbff7eb1e9 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_45f540823942570f0f663af23049a49d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10399 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9601 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d5b1b2321208a878d2295fcc0b97930f http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7987 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7992 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c73966f4f68c5cfd75b54c0b1fd40f70

Total number of triples: 72.